melphalan has been researched along with azelaic-acid* in 2 studies
2 other study(ies) available for melphalan and azelaic-acid
Article | Year |
---|---|
The effects of different antineoplastic agents and of pretreatment by modulators on three melanoma lines.
The chemotherapy of melanoma patients must be improved because of the naturally poor response and acquired resistance of this disease.. The authors used mouse (B16F10) and human (SK-MEL-28 and SK-MEL-1) melanoma lines for in vitro treatment with melphalan, lomustine, fotemustine, and 4-hydroxyanisole (4-HA) alone, combined and after pretreatment with buthionine sulfoximine (BSO), ethacrynic acid (EA), and azelaic acid (AZA).. Melphalan was the most effective individual drug, followed by lomustine, fotemustine, and 4-HA. The simultaneous administration of two agents was disappointing, although some combinations slightly improved the response compared with the individual treatments. Pretreatment with BSO enhanced the cytotoxicity of melphalan and lomustine 10-fold in B16F10 and 7.5-fold in SK-MEL-28, increasing the toxicity of fotemustine in all 3 lines. EA potentiated lomustine and fotemustine 9-fold and melphalan 5-fold in B16F10 and SK-MEL-28. AZA increased the effectiveness of lomustine and fotemustine in B16F10 and to a lower degree in the two human lines. 4-HA was the poorest drug for sensitization; only B16F10 BSO followed by 4-HA treatment demonstrated increased toxicity, and all other combinations with 4-HA were negative or antagonistic. There was a strong relationship between dopa oxidase activity and the toxicity of 4-HA.. B16F10 was the most sensitive to all treatments and SK-MEL-1 the most resistant. Melphalan was the most active individual drug and 4-HA the least. Combinations of two drugs did not result in improved activity compared with drugs administered alone. Pretreatment with modulator seems to be a potential method for enhancing some treatments. Topics: Animals; Anisoles; Antineoplastic Agents; Buthionine Sulfoximine; Dicarboxylic Acids; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Ethacrynic Acid; Humans; In Vitro Techniques; Lomustine; Melanoma, Experimental; Melphalan; Mice; Monophenol Monooxygenase; Nitrosourea Compounds; Organophosphorus Compounds; Tumor Cells, Cultured | 1998 |
Azelaic acid was sensitizing effect in the chemotherapeutic treatment of several melanoma cell lines.
Chemotherapy for melanoma results in low response and must be reinforced with sensitizer compounds. We believed that azelaic acid (AZA) could modulate melanomas' resistance to antineoplastics. Therefore we tried to compare in vitro treatment with antineoplastics alone versus AZA treatment followed by antineoplastics. We carried out MTT assays to evaluate the cytotoxicity of melphalan, lomustine (CCNU), fotemustine, and 4-Hydroxyanisole (4-HA) on three melanoma lines (B16F10, SK-MEL-28, and SK-MEL-1), and the modulating effect of pretreatment with AZA (1 mM). AZA showed a dose-dependent antineoplastic activity on the three lines. Melphalan was the most active drug followed by CCNU, fotemustine, and 4-HA. The most sensitive line was B16F10 and the least sensitive was SK-meL-1. Previous treatment with AZA of B16F10 reinforced the effect of melphalan (2.5 times), CCNU (10 times), and fotemustine (14 times); whereas for SK-MEL-28 and SK-MEL-1, only the cytotoxicity of CCNU and fotemustine increased. An antagonist effect was produced by 4-HA on all three lines. We concluded that AZA enhances in vitro cytotoxicity of CCNU and fotemustine. Topics: Animals; Anisoles; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Differentiation; Cell Division; Dicarboxylic Acids; Dose-Response Relationship, Drug; Drug Synergism; Humans; Lomustine; Melanoma; Melphalan; Mice; Microscopy, Electron, Scanning; Monophenol Monooxygenase; Tumor Cells, Cultured; Vacuoles | 1996 |